<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930810</url>
  </required_header>
  <id_info>
    <org_study_id>METc2017.106</org_study_id>
    <nct_id>NCT03930810</nct_id>
  </id_info>
  <brief_title>NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion</brief_title>
  <acronym>NAPPED</acronym>
  <official_title>NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion (NAPPED Study), Meta-analysis of Individual Patient Data of PFIC Before and After Surgery (Bile Diversion or Liver Transplantation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The natural course of PFIC syndromes and the effect of diversion techniques, have so far not
      been characterized in a rigorous manner within a larger population of patients. In fact, the
      clinical or biochemical parameters which most directly define and/or predict the success of
      reduced enterohepatic circulation (either by surgical diversion or medically) are still
      unclear.

      The present project aims to:

        1. Define the natural course of disease in genetically defined PFIC1, and PFIC2 patients,
           with respect to relevant biochemical and clinical parameters (and if available,
           histological). Included will be patients homozygous for a known, disease-causing
           mutation, patients compound homozygous for two disease-causing mutations or heterozygous
           for one disease-causing mutation in combination with the clinical phenotype of
           Bsep-deficiency or FIC1-deficiency.

        2. Define the change in the natural course of disease in response to biliary diversion
           surgery and or liver transplantation, based on short- and long(er)-term changes in
           biochemical (if available, histological) and clinical parameters, including outcome
           measures. Follow up after transplantation will be limited to max 3 months after
           transplant surgery, follow up after surgical biliary diversion will be as long as
           possible.

        3. Assessment of biochemical variables as possible surrogate endpoints for clinical hard
           endpoints. If possible this allows for identification of low-risk to high-risk patients
           early during follow-up.

        4. If patient numbers permit, to establish genotype-phenotype relationships for the most
           common genetic mutations causing Bsep-deficiency or FIC1-deficiency.

      Based on this project it is anticipated that the investigators are able:

        -  to characterize the variation in natural course of disease (whether or not genotype
           dependent) to allow clinicians to rationally select a target population for assessing
           the effect of medical intervention, rather than surgical biliary diversion);

        -  to identify and qualify one or more biomarkers that independently predict either
           improved or poor clinical outcomes of surgical biliary diversion;

        -  to investigate if the identified biomarker(s) can be used as surrogate end point(s) for
           assessing and predicting outcomes with novel interventional strategies.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 26, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with liver transplantation</measure>
    <time_frame>at 18 years of age</time_frame>
    <description>Underwent liver transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that succumbed</measure>
    <time_frame>at 18 years of age</time_frame>
    <description>Succumbed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participant undergoing a surgical biliary diversion</measure>
    <time_frame>at 5, 10, 15 and 18 years of age</time_frame>
    <description>Underwent surgical biliary diversion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">582</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis</condition>
  <arm_group>
    <arm_group_label>FIC1-deficiency and Bsep-deficiency</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical biliary diversion</intervention_name>
    <description>Surgical interruption of enterohepatic circulation</description>
    <arm_group_label>FIC1-deficiency and Bsep-deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The diagnosis of PFIC needs to be performed according to the international guidelines,
        based on (episodes with a) low gamma-GT cholestasis and identification of disease-causing
        mutations in PFIC-1 (ATP8B1) or PFIC 2 (ABCB11) genes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical suspicion for Bsep- or FIC1-deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, Wanty C, Fischler B, Jacquemin E, Wali S, Blanchard S, Nielsen IM, Bourke B, McQuaid S, Lacaille F, Byrne JA, van Eerde AM, Kolho KL, Klomp L, Houwen R, Bacchetti P, Lobritto S, Hupertz V, McClean P, Mieli-Vergani G, Shneider B, Nemeth A, Sokal E, Freimer NB, Knisely AS, Rosenthal P, Whitington PF, Pawlowska J, Thompson RJ, Bull LN. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol. 2010 Jul;53(1):170-8. doi: 10.1016/j.jhep.2010.01.034. Epub 2010 Apr 13.</citation>
    <PMID>20447715</PMID>
  </reference>
  <reference>
    <citation>Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L, Meier Y, Antoniou A, Stieger B, Arnell H, Ozçay F, Al-Hussaini HF, Bassas AF, Verkade HJ, Fischler B, Németh A, Kotalová R, Shneider BL, Cielecka-Kuszyk J, McClean P, Whitington PF, Sokal E, Jirsa M, Wali SH, Jankowska I, Pawłowska J, Mieli-Vergani G, Knisely AS, Bull LN, Thompson RJ. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008 Apr;134(4):1203-14. doi: 10.1053/j.gastro.2008.01.038. Epub 2008 Jan 18.</citation>
    <PMID>18395098</PMID>
  </reference>
  <reference>
    <citation>Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LW, Lomri N, Berger R, Scharschmidt BF, Knisely AS, Houwen RH, Freimer NB. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet. 1998 Mar;18(3):219-24.</citation>
    <PMID>9500542</PMID>
  </reference>
  <reference>
    <citation>Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, Bernard O, Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010 May;51(5):1645-55. doi: 10.1002/hep.23539.</citation>
    <PMID>20232290</PMID>
  </reference>
  <reference>
    <citation>Bull LN, Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Dodge JL, Emerick K, Wanty C, Wali S, Blanchard S, Lacaille F, Byrne JA, van Eerde AM, Kolho KL, Houwen R, Lobritto S, Hupertz V, McClean P, Mieli-Vergani G, Sokal E, Rosenthal P, Whitington PF, Pawlowska J, Thompson RJ. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun. 2018 Mar 30;2(5):515-528. doi: 10.1002/hep4.1168. eCollection 2018 May.</citation>
    <PMID>29761168</PMID>
  </reference>
  <reference>
    <citation>Dröge C, Bonus M, Baumann U, Klindt C, Lainka E, Kathemann S, Brinkert F, Grabhorn E, Pfister ED, Wenning D, Fichtner A, Gotthardt DN, Weiss KH, McKiernan P, Puri RD, Verma IC, Kluge S, Gohlke H, Schmitt L, Kubitz R, Häussinger D, Keitel V. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol. 2017 Dec;67(6):1253-1264. doi: 10.1016/j.jhep.2017.07.004. Epub 2017 Jul 19.</citation>
    <PMID>28733223</PMID>
  </reference>
  <reference>
    <citation>Wang KS, Tiao G, Bass LM, Hertel PM, Mogul D, Kerkar N, Clifton M, Azen C, Bull L, Rosenthal P, Stewart D, Superina R, Arnon R, Bozic M, Brandt ML, Dillon PA, Fecteau A, Iyer K, Kamath B, Karpen S, Karrer F, Loomes KM, Mack C, Mattei P, Miethke A, Soltys K, Turmelle YP, West K, Zagory J, Goodhue C, Shneider BL; Childhood Liver Disease Research Network (ChiLDReN). Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology. 2017 May;65(5):1645-1654. doi: 10.1002/hep.29019. Epub 2017 Mar 22.</citation>
    <PMID>28027587</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Henkjan J. Verkade</investigator_full_name>
    <investigator_title>Principal Investigator, Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

